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Background: With data from a diverse sample of patients either in treatment for cancer or post-treatment for
cancer, we examine inter-domain and cross-domain correlations among the core domains of the Patient-Reported
Outcomes Measurement Information System Sexual Function and Satisfaction measures (PROMISW SexFS) and the
corresponding domains from conceptually-similar measures of sexual function, the International Index of Erectile
Function and the Female Sexual Function Index.
Findings: Men (N=389) and women (N=430) were recruited from a tumor registry, oncology clinics, and an internet
panel. The PROMIS SexFS, International Index of Erectile Function, and Female Sexual Function Index were used to
collect participants’ self-reported sexual function. The domains shared among the measures include desire/interest
in sexual activity, lubrication and vaginal discomfort/pain (women), erectile function (men), orgasm, and satisfaction.
We examined correlations among different domains within the same instrument (discriminant validity) and
correlations among similar domains measured by different instruments (convergent validity). Correlations
demonstrating discriminant validity ranged from 0.38 to 0.73 for men and 0.48 to 0.74 for women, while
correlations demonstrating convergent validity ranged from 0.62 to 0.83 for men and 0.71 to 0.92 for women. As
expected, correlations demonstrating convergent validity were higher than correlations demonstrating discriminant
validity, with one exception (orgasm for men).
Conclusions: Construct validity was supported by convergent and discriminant validity in a diverse sample of
patients with cancer. For patients with cancer who may or may not have sexual dysfunction, the PROMIS SexFS
measures provide a comprehensive assessment of key domains of sexual function and satisfaction.
Keywords: Patient-reported outcome measures, Measurement, Validity, Quality of life, Male and female sexual
dysfunction, CancerFindings
Background
The Patient-Reported Outcomes Measurement Informa-
tion SystemW Sexual Function and Satisfaction measures
(PROMISW SexFS) are a newly-developed collection of
measures to assess sexual function and satisfaction in
men and women. They were developed based on exten-
sive qualitative and quantitative research with cancer
patients [1-4]. Recent reports support the measures’ con-
tent validity (based on patient and clinician focus group* Correspondence: kflynn@mcw.edu
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reproduction in any medium, provided the ordata regarding relevant sexual concepts) [3], face validity
(based on cognitive interview data) [2], and discrimin-
ation between known groups of patients who had (or
had not) asked a provider for help with sexual problems
[4]. However, no published report has provided compre-
hensive evaluation of the convergent and discriminant
validity of the core PROMIS SexFS measures.
The extent to which the PROMIS SexFS is used in re-
search rests on the strength of evidence for the validity
of the measures, that is, the degree to which the instru-
ment measures what it is intended to measure [5-7]. In
this paper we present evidence of construct validity in a
diverse sample of patients with cancer. Specifically, we
evaluate the relationship among the core PROMIS SexFS
domains and subscales drawn from two frequently-used
measures in cancer research, the International Index oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Sample characteristics overall and by male/
female sex (N=819)
Characteristic Total
(N = 819)
Men
(N = 389)
Women
(N = 430)
Age, mean ± SD, y 58.5 ± 11.8 61.4 ± 10.8 55.9 ± 12.2
Age group, No. (%)
≤ 40 years 59 (7) 14 (4) 45 (10)
41 to 50 years 127 (16) 29 (7) 98 (23)
51 to 64 years 377 (46) 197 (51) 180 (42)
65 to 79 years 232 (28) 134 (35) 98 (23)
≥ 80 years 21 (3) 13 (3) 8 (2)
Race, No. (%)
Black or African American 80 (10) 39 (10) 41 (10)
American Indian/
Alaska Native
10 (1) 6 (2) 4 (<1)
Asian 12 (1) 2 (<1) 10 (2)
Native Hawaiian/
Other Pacific Islander
2 (<1) 1 (<1) 1 (<1)
White 705 (87) 338 (87) 367 (86)
Multiple races or other 6 (<1) 1 (<1) 5 (<1)
Hispanic or Latino ethnicity,
No. (%)
21 (3) 10 (3) 11 ( 3)
Educational attainment,
No. (%)
Less than high school 24 (3) 14 (4) 10 ( 2)
High school graduate/GED 100 (12) 35 (9) 65 (15)
Some college 255 (31) 122 (31) 133 (31)
College degree 229 (28) 114 (29) 115 (27)
Advanced degree
(MA, PhD, MD)
211 (26) 104 (27) 107 (25)
Treatment status in past
month, No. (%)
None (ie, posttreatment
follow-up)
526 (64) 290 (75) 236 (55)
Undergoing treatment 290 (36) 98 (25) 192 (45)
Radiation therapy 29 (4) 15 (4) 14 (3)
Hormonal therapy
(eg, tamoxifen, anastrozole,
leuprolide)
140 (17) 28 (7) 112 (26)
Chemotherapy
(injection or oral)
116 (14) 46 (12) 70 (16)
Immunotherapy
(eg, interferon)
9 (1) 2 (<1) 7 (2)
Other 36 (4) 17 (4) 19 (4)
Recurrence of cancer, No. (%) 151 (18) 68 (17) 83 (19)
Cancer spread to lymph
nodes, No. (%)
202 (25) 68 (17) 134 (31)
Cancer spread to another
area, No. (%)
134 (16) 57 (15) 77 (18)
Primary cancer diagnosis,
No. (%)
Breast cancer 252 (35) 1 (<1) 251 (62)
Table 1 Sample characteristics overall and by male/
female sex (N=819) (Continued)
Colorectal 98(13) 57 (18) 41 (10)
Gynecologic cancer 29 (4) – 29 (7)
Lung cancer 56 (8) 35 (11) 21 (5)
Prostate cancer 146 (20) 146 (45) –
Other or Unknown 9 (1) 6 (2) 3 (<1)
Percentages may not sum to 100 because of rounding.
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tion Index [FSFI] [9]). While a limited number of corre-
lations between PROMIS SexFS and pre-specified IIEF
and FSFI subscales were reported in a previous psycho-
metric report [4], it did not provide comprehensive evi-
dence of construct validity, including the magnitude of
relationships across differing sexual function domains
both within and across measures. In the current report
we provide this evidence using a multi-trait multi-
method approach [10]. We expect to observe stronger
relationships between different measures of the same do-
main (e.g., sexual interest) as compared with relation-
ships between different domains measured within the
same instrument (e.g., sexual interest and orgasm).
Methods
Data collection
Data collection for the development of the PROMIS SexFS
has been described in detail elsewhere [4]. Briefly, English-
speaking adult patients who had been diagnosed with can-
cer were recruited from clinics, a tumor registry, and an
internet panel. Participants completed static surveys
online or by interviewer-administrated telephone survey.
The institutional review board of the Duke University
Medical Center approved this study, and all patient partic-
ipants provided informed consent.
Procedure
Most participants completed surveys online (79%), though
participants were given the option to complete the survey
by interviewer-administered telephone survey. Rates of
survey completion were comparable by mode of adminis-
tration. Those who opted for the telephone administration
were significantly older (68 vs. 60 years), less likely to be
married (64% vs. 81%), of lower household income level
(<$50,000, 54% vs. 24%), and less likely to be white (71%
vs. 89%). An evaluation of differential item functioning
(DIF) by mode of administration suggested there was no
DIF for phone vs. online administration [4].
Measures
Items in the PROMIS SexFS, IIEF, and FSFI are rated on
a 5-point scale regarding sexual function experienced
over the past 30 days.
PROMIS IIEF 
Interest Satisfaction Orgasm Erectile 
Function
Sexual 
Desire 
Intercourse 
Satisfaction 
Overall 
Satisfaction 
Orgasmic 
Function 
Erectile 
Function 
P
R
O
M
IS
 Interest 
Satisfaction 0.38   Monotrait-heteromethod    
Orgasm 0.53 0.68   Heterotrait-monomethod    
Erectile function 0.43 0.66 0.73   Heterotrait-heteromethod  
IIE
F
 
Sexual Desire 0.82 0.46 0.57 0.50 
Intercourse Satisfaction 0.30 0.76 0.67 0.76 0.41 
Overall Satisfaction 0.20 0.83 0.51 0.57 0.30 0.73 
Orgasmic Function 0.16 0.57 0.62 0.60 0.29 0.62 0.51 
Erectile Function 0.46 0.71 0.76 0.83 0.51 0.82 0.62 0.61 
Abbreviations: PROMIS Patient Reported Outcomes Measurement Information System; IIEF International Index of Erectile Function 
Figure 1 Correlations for men (N=390).
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separate domains for interest in sexual activity (4 items),
global satisfaction with sex life (7 items), orgasm (1 item),
erectile function (8 items, men only), lubrication (8 items,
women only) and vaginal discomfort (10 items, women
only). In the current version of the PROMIS SexFS meas-
ure, the 4 FSFI lubrication items are included in the
PROMIS lubrication scale and the 3 FSFI pain items are
included in the PROMIS vaginal discomfort scale. For
items/domains describing function, respondents are
treated as missing (not given a score) if they report no
sexual activity in the past 30 days. More information
about the measure and item wording is available on the
Assessment Center (http://www.assessmentcenter.net).
The IIEF measures sexual dysfunction in men and in-
cludes subscales for sexual desire (2 items), intercourse
satisfaction (3 items), overall satisfaction (2 items), orgas-
mic function (3 items), and erectile function (6 items). Re-
spondents are given a score of zero on items/domains
describing function if they report no sexual activity in the
past 30 days.PROMIS 
Interest Satisfaction Orgasm Vaginal 
Discomfort 
Lubr
P
R
O
M
IS
 
Interest 
Satisfaction 0.48 
Orgasm 0.66 0.51 
Vaginal 
discomfort -0.47 -0.57 -0.46 
Lubrication 0.46 0.57 0.43 -0.74 
F
S
F
I 
Desire 0.84 0.59 0.63 -0.51 0
Arousal 0.71 0.72 0.70 -0.54 0
Satisfaction 0.49 0.76 0.54 -0.42 0
Orgasm 0.49 0.56 0.76 -0.46 0
Pain 0.40 0.54 0.41 -0.90a 0
Lubrication 0.47 0.60 0.46 -0.68 0
Abbreviations: PROMIS Patient Reported Outcomes Measurement Informa
aSome items from the FSFI Pain subdomain are included in the PROMIS Va
bSome items from the FSFI Lubrication subdomain are included in the PRO
Figure 2 Correlations for women (N=429).The FSFI measures sexual dysfunction in women and
includes subscales for sexual desire (2 items), arousal
(4 items), satisfaction (3 items), orgasm (3 items), pain
(3 items) and lubrication (4 items). Respondents are
given a score of zero on items/domains describing
function if they report no sexual activity in the past
30 days.
Data analysis
Pearson’s product moment correlation coefficients were
used to evaluate the strength of relationships across
sexual function domains as part of a multi-trait multi-
method test of convergent and discriminant validity [10].
Data were managed and analyzed using SAS version 9.2
(SAS Institute Inc, Cary, North Carolina).
Results
Sample characteristics are reported in Table 1. Of the
full sample of 819 patients, 56% of men and 59% of
women reported engaging in sexual activity over the past
30 days (this is not representative of rates of sexualFSFI 
ication Desire Arousal Satisfaction Orgasm Pain Lubrica
tion 
Monotrait-heteromethod 
Heterotrait-monomethod 
Heterotrait-heteromethod 
.55 
.58 0.75 
.41 0.59 0.69 
.50 0.48 0.68 0.39    
.72 0.46 0.50 0.45 0.43   
.92b 0.55 0.60 0.51 0.48 0.70  
tion System; FSFI Female Sexual Function Index 
ginal Discomfort subdomain. 
MIS Lubrication subdomain.
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and 2 show correlations among domains for men and
women, respectively. The correlations describing dis-
criminant validity are shaded in blue gingham (within an
instrument) or green stripes (from different instru-
ments). The correlations describing convergent validity
are shaded in solid yellow. All correlations were signifi-
cantly different from zero (p<0.0001).
Convergent validity – men
The PROMIS interest in sexual activity and IIEF sexual
desire domains had large correlations (r=0.82), as did
the PROMIS and IIEF erectile function domains (r=0.83)
and the PROMIS and IIEF general satisfaction domains
(r=0.83). The PROMIS orgasm and IIEF orgasmic func-
tion domains were less highly correlated (r=0.62).
Discriminant validity – men
The PROMIS interest in sexual activity was the least
highly correlated with the other PROMIS domains of
erectile function, orgasm, and global satisfaction with
sex life (r=0.38 to r=0.53). Erectile function was corre-
lated with orgasm at r=0.73 and global satisfaction with
sex life at r=0.66. Orgasm and global satisfaction with
sex life were also correlated with each other at r=0.68.
The correlations across domains were smaller than the
correlations within domains with the exception of the
PROMIS orgasm domain, which had higher correlations
with PROMIS Satisfaction (r=0.68) and with PROMIS
Erectile Function (r=0.73) than with IIEF orgasm (r=0.62).
Convergent validity – women
The PROMIS interest in sexual activity and FSFI desire
domains had large correlations, as did the PROMIS and
FSFI lubrication domains, and the PROMIS vaginal dis-
comfort and FSFI pain domains (rs>0.8). Both the
PROMIS and FSFI satisfaction domains and the PROMIS
and FSFI orgasm domains were correlated at r=0.76.
Discriminant validity – women
Among PROMIS domains, interest in sexual activity was
moderately correlated with lubrication, vaginal discom-
fort, orgasm, and global satisfaction with sex life (r=0.46
to r=0.66). Lubrication was correlated with vaginal dis-
comfort at r=−0.74, orgasm at r=0.43, and global satis-
faction with sex life at r=0.57. Orgasm and global
satisfaction with sex life were correlated with each other
at r=0.51.
For women, all correlations within domains were higher
than those across domains.
Conclusions
Concurrent validity for the PROMIS SexFS measures was
generally supported by convergent and discriminantvalidity in a diverse sample of patients with cancer. The
correlations across different domains within the PROMIS
measures were smaller than the correlations within similar
domains across different sexual function measures. The
exception to this was the PROMIS orgasm domain, which
was more highly correlated with the satisfaction and erect-
ile function domains than with the IIEF orgasm domain.
Likewise, the IIEF orgasm domain was more highly corre-
lated with the IIEF intercourse satisfaction and erectile
function domains than with the PROMIS orgasm domain.
The high correlations between orgasm and both satisfac-
tion and erectile function should prompt consideration of
the additional value of the orgasm domain for men, and
the amount of data this domain provides beyond measures
of erectile function and satisfaction. However, we note that
focus group data support the inclusion of a separate or-
gasm domain for males, as men typically described orgasm
as related to, but never conceptually the same as, erectile
function or satisfaction. In the current version of the
measure, the PROMIS orgasm domain includes a single
item that asks respondents to rate their ability to have a
satisfying orgasm. The IIEF includes one item on fre-
quency of orgasm and one item on frequency of ejacula-
tion. We wondered if there might be a higher correlation
between the items asking about orgasm rather than ejacu-
lation, but the correlation between the PROMIS and IIEF
orgasm items was only slightly higher than the correlation
between the PROMIS orgasm item and the IIEF ejacula-
tion item (0.63 vs 0.58). These results suggest the need for
broader assessment of the domain of orgasm, and we are
testing additional items for version 2 of the PROMIS
SexFS orgasm domain.
Our sample, while generally large and diverse, did not
adequately represent people with cancers other than the
most common ones (breast or prostate). People of non-
white race and non-Hispanic ethnicity were also not well
represented, nor were people with less than a college
education.
In conclusion, scores on the PROMIS SexFS behaved
as expected in relation to two well-regarded measures of
sexual function, the IIEF and FSFI. This study adds to
the validity data in support of the use of the freely-
available PROMIS SexFS to comprehensively assess key
domains of sexual function and satisfaction.
Abbreviations
PROMISW SexFS: Patient-Reported Outcomes Measurement Information
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